HIMS Stock Is Crashing Today — But Analysts Think The Real Story Is Just Beginning

• Citi raised the price target to $28 from $24 and kept a ‘Neutral’ rating, according to The Fly.
• Needham highlighted the company’s renewed partnership with Novo Nordisk, which is already seeing strong early demand for weight-loss subscriptions.
• Hims & Hers Health raised its revenue guidance for full year-2026 to $2.8 billion - $3.0 billion from an earlier forecast of $2.7 billion - $2.9 billion

Shares of Hims & Hers Health, Inc. plunged more than 15% in pre-market trading on Tuesday after the telehealth company posted a sharp first-quarter earnings miss, rattling investors even as Wall Street firms largely maintained confidence in its long-term growth story.

The company reported first-quarter revenue of $608.1 million, up 4% but below Wall Street expectations of $616.85 million, according to Fiscal.ai data. HIMS also posted a loss of $0.40 per share, sharply missing analysts’ estimates for earnings of $0.03 per share.

Brokerages Remain Bullish On HIMS

Citi was among the first brokerages to issue coverage on HIMS after the earnings. The firm raised the price target to $28 from $24 and kept a ‘Neutral’ rating, according to The Fly. Analyst Daniel Grosslight said the company is moving into a transition period as it reduces its dependence on compounded GLP-1 products.

Needham too raised its price target to $35 from $30 while maintaining a ‘Buy’ rating, according to a report by investing.com. The firm pointed to the company’s renewed partnership with Novo Nordisk (NVO), which is already seeing strong early demand for weight-loss subscriptions. Needham flagged optimism around the company’s long-term growth potential.

Canaccord Genuity raised its price to $32 from $30 and maintained a ‘Buy’ rating on the stock. The firm said growth was affected by tough year-over-year comparisons following strong weight-loss customer additions last year, as well as shorter shipping cycles linked to its shift toward branded GLP-1 products.

However, JPMorgan lowered its price target to $33 from $35 but kept an ‘Overweight’ rating, citing “mixed” Q1 results and an updated 2026 outlook that reflects the strategic shift from compounded to branded GLP-1.

HIMS Raises FY2026 Outlook Following Shift To Branded GLP-1 Products

Hims & Hers Health raised its revenue guidance for full year-2026 to $2.8 billion - $3.0 billion from an earlier forecast of $2.7 billion - $2.9 billion. Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin was also raised to 10% - 12%, up significantly from an earlier guidance between 6% and 9%.

“We expect growth to accelerate from here, and have high conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA,” said CFO Yemi Okupe.

Retail Debates Consequences of HIMS Q1 Results

Despite the pre-market slump, retail sentiment on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier, while message volumes surged more than 1,350% over a 24-hour period.

Retail traders remained sharply divided on whether the post-earnings selloff represented a temporary reset or a deeper warning sign for Hims & Hers’ GLP-1 strategy. One user expected the stock to climb above $40.

However, another user expects prices to fall further, adding that “it just doesn’t work without mass compounding.”

The stock is down nearly 15% so far this year.

Read also: Why Did HTCO Stock Surge 25% In Pre-Market Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.